Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2017

Open Access 01-12-2017 | Research

Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration

Authors: Erlangga Yusuf, Bruno Van Herendael, Walter Verbrugghe, Margareta Ieven, Emiel Goovaerts, Kristof Bergs, Kristien Wouters, Philippe G. Jorens, Herman Goossens

Published in: Annals of Intensive Care | Issue 1/2017

Login to get access

Abstract

Background

Antibiotics are frequently used in intensive care units (ICUs), and their use is associated with the emergence of bacterial resistance to antibiotics. The aim of this study was to investigate the association between the emergence of Pseudomonas aeruginosa resistance and the duration of antibiotic exposure or mode of administration in an ICU unit.

Methods

A 4-year cohort study of intensive care unit was performed in patients with P. aeruginosa isolates from clinical specimens, initially susceptible to the investigated antibiotics (piperacillin/tazobactam, ceftazidime, ciprofloxacin, meropenem and amikacin). Odds ratios (ORs) with 95% confidence interval (95% CI) of emergence of resistance were calculated using logistic regression analysis for various exposure periods to antibiotics (1–3, 4–7, 8–15 and >15 days) relative to no exposure with adjustment for age, sex, Simplified Acute Physiology Score 3 (SAPS 3) and length of stay. ORs on the emergence of P. aeruginosa resistance were also calculated for the various modes of administration.

Results

Included were 187 patients [mean age 61 years, 69% male, mean SAPS 3 score (SD): 59 (12.3)]. None of the antibiotics investigated showed the emergence of resistance within 1–3 days. Significant meropenem resistance emerged within 8–15 days [OR 79.1 (14.9–421.0)] after antibiotic exposure unlike other antibiotics (>15 days). No difference was observed between intermittent and extended administration of meropenem and between beta-lactam mono- or combined therapy.

Conclusions

Use of meropenem was associated with the emergence of resistance as soon as 8 days after exposure to the antibiotic.
Literature
1.
ECDC. European Centre for Disease Prevention and Control. Point prevalence survey of healthcareassociated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.
2.
ECDC. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2015.
3.
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Internet]. Ecdc; 2014. p. 1–211.
4.
Cobos-Trigueros N, Solé M, Castro P, Torres JL, Hernández C, Rinaudo M, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care. 2015;19:218.CrossRefPubMedPubMedCentral
5.
Peña C, Suarez C, Tubau F, Dominguez A, Sora M, Pujol M, et al. Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur J Clin Microbiol Infect Dis. 2009;28(5):519–22.CrossRefPubMed
6.
Lodise TP, Miller C, Patel N, Graves J, McNutt LA. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect Control Hosp Epidemiol. 2007;28(8):959–65.CrossRefPubMed
7.
Ong DS, Jongerden IP, Buiting AG, Leverstein-van Hall MA, Speelberg B, Kesecioglu J, et al. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med. 2011;39(11):2458–63.CrossRefPubMed
8.
MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014;43(2):105–13CrossRefPubMed
9.
Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents. 2013;41(4):301–10CrossRefPubMed
10.
Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane database Syst Rev [Internet]. 2013;6(6):CD003038.
11.
Moreno RP, Metnitz PGH, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3–from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005;31(10):1345–55.CrossRefPubMedPubMedCentral
12.
CLSI. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. 2010; p. 1–153.
13.
14.
Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. J Am Med Assoc. 2003;290(19):2588–98.CrossRef
15.
Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43(6):1379–82.PubMedPubMedCentral
16.
Georges B, Conil J-M, Dubouix A, Archambaud M, Bonnet E, Saivin S, et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med. 2006;34(6):1636–41.CrossRefPubMed
17.
Martínez JA, Delgado E, Martí S, Marco F, Vila J, Mensa J, et al. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med. 2009;35(3):439–47.CrossRefPubMed
18.
Feng Y, Jonker MJ, Moustakas I, Brul S, ter Kuile BH. Dynamics of mutations during development of resistance by Pseudomonas aeruginosa against Five Antibiotics. Antimicrob Agents Chemother Internet. 2016;60(7):4229–36.CrossRef
19.
Solé M, Fàbrega A, Cobos-Trigueros N, Zamorano L, Ferrer-Navarro M, Ballesté-Delpierre C, et al. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure. J Antimicrob Chemother. 2015;70(11):3004–13.CrossRefPubMed
20.
Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(12):4920–7.CrossRefPubMedPubMedCentral
21.
De Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 2014;40(7):998–1005.CrossRefPubMed
Metadata
Title
Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration
Authors
Erlangga Yusuf
Bruno Van Herendael
Walter Verbrugghe
Margareta Ieven
Emiel Goovaerts
Kristof Bergs
Kristien Wouters
Philippe G. Jorens
Herman Goossens
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Intensive Care / Issue 1/2017
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-017-0296-z

Other articles of this Issue 1/2017

Annals of Intensive Care 1/2017 Go to the issue

Research

A new global and comprehensive model for ICU ventilator performances evaluation

Review

Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care

Research article

Nasal high flow in management of children with status asthmaticus: a retrospective observational study

Research

Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study

Research

Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an intensive care unit with no single rooms

Research

Impact of random safety analyses on structure, process and outcome indicators: multicentre study